Genocea Biosciences Inc Valor contable por acción
¿Qué es el Valor contable por acción de Genocea Biosciences Inc?
El Valor contable por acción de Genocea Biosciences Inc es 0.00
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en NASDAQ en comparadas con Genocea Biosciences Inc
¿Qué hace Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Empresas con valor contable por acción similar a Genocea Biosciences Inc
- Cycliq tiene Valor contable por acción de 0.00
- B. Riley Principal Merger II tiene Valor contable por acción de 0.00
- FG Acquisition tiene Valor contable por acción de 0.00
- Nexway AG tiene Valor contable por acción de 0.00
- THC Therapeutics tiene Valor contable por acción de 0.00
- Thoma Bravo Advantage tiene Valor contable por acción de 0.00
- Genocea Biosciences Inc tiene Valor contable por acción de 0.00
- Canada Rare Earth tiene Valor contable por acción de 0.00
- Galilee tiene Valor contable por acción de 0.00
- PT Aneka Tambang Tbk tiene Valor contable por acción de 0.00
- Coho Collective Kitchens tiene Valor contable por acción de 0.00
- My Rewards International Ltd tiene Valor contable por acción de 0.00
- Six Sigma Metals tiene Valor contable por acción de 0.00